Clinical Trials Logo
  1. Home
  2. Neoplasms, Head and Neck
  3. NCT06256588

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma — JADE  

Neoplasms, Head and Neck Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Clinical Trial Summary

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06256588
Study type Interventional
Source GlaxoSmithKline
Contact US GSK Clinical Trials Call Center
Phone 877-379-3718
Email GSKClinicalSupportHD@gsk.com
Status Not yet recruiting
Phase Phase 3
Start date March 4, 2024
Completion date July 13, 2029
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01370876 - Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT03178110 - Manual Therapy and Use of the Dynasplint for Trismus in Patients With Head and Neck Cancer N/A
Terminated NCT04128696 - Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 2/Phase 3
Completed NCT00798655 - Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase 2
Completed NCT00387127 - Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer Phase 2
Recruiting NCT06062420 - Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Phase 2
Active, not recruiting NCT04260126 - Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC Phase 2
Active, not recruiting NCT02296684 - Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT01116336 - Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck Phase 1
Completed NCT01110980 - Normalcy of Food Intake in Head and Neck Cancer Patients N/A
Recruiting NCT02557048 - Head and Neck Cancer in Children: A Retrospective Study
Completed NCT03356093 - Change in Symptom Clusters in HNC Patients N/A
Terminated NCT02376699 - Safety Study of SEA-CD40 in Cancer Patients Phase 1
Completed NCT00424255 - Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Phase 3
Completed NCT00725764 - Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck Phase 2
Terminated NCT04428333 - Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 2/Phase 3
Active, not recruiting NCT02573493 - Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) Phase 2